Exploration of Clinical Breakpoint of Danofloxacin for <i>Glaesserella parasuis</i> in Plasma and in PELF

Exploration of Clinical Breakpoint of Danofloxacin for <i>Glaesserella parasuis</i> in Plasma and in PELF

<b>Background:</b> In order to establish the clinical breakpoint (CBP) of danofloxacin against <i>G. parasuis</i>, three cutoff values, including epidemiological cutoff value (ECV), pharmacokinetic-pharmacodynamic (PK-PD) cutoff value (CO<sub>PD</sub>) and clinica...

Full description

Bibliographic Details
Main Authors: Zihui Xu, Anxiong Huang, Xun Luo, Peng Zhang, Lingli Huang, Xu Wang, Kun Mi, Shiwei Fang, Xiao Huang, Jun Li, Zonghui Yuan, Haihong Hao
Format: Article
Language:English
Published: MDPI AG 2021-07-01
Series:Antibiotics
Subjects:
danofloxacin
<i>Glaesserella parasuis</i>
epidemiological cutoff values
PK-PD cutoff values
clinical cutoff values
clinical breakpoint
Online Access:https://www.mdpi.com/2079-6382/10/7/808

Internet

https://www.mdpi.com/2079-6382/10/7/808

Similar Items